A HYBRID DECISION-MAKING STRATEGY WITH INSTANTANEOUS WAVE-FREE RATIO AND FRACTIONAL FLOW RESERVE COULD ENHANCE ADOPTION OF PHYSIOLOGY-GUIDED CORONARY REVASCULARISATION  by Petraco da Cunha, Ricardo et al.
Chronic CAD/Stable Ischemic Heart Disease
E1182
JACC March 12, 2013
Volume 61, Issue 10
a hyBrid decision-making sTraTegy wiTh insTanTaneous wave-free raTio and 
fracTional flow reserve could enhance adopTion of physiology-guided coronary 
revascularisaTion
Moderated Poster Contributions
Poster Sessions, Expo North
Sunday, March 10, 2013, 9:45 a.m.-10:30 a.m.
Session Title: When to Intervene or Not in Stable Ischemic Heart Disease
Abstract Category: 10. Chronic CAD/Stable Ischemic Heart Disease: Clinical
Presentation Number: 1195M-71
Authors: Ricardo Petraco da Cunha, Jin Joo Park, Sayan Sen, Sukhjinder Nijjer, Echavarría-Pinto Mauro, Chang-Wook Nam, Kaleab Asrress, Javier 
Escaned, Amarjit Sethi, Alun Hughes, Jamil Mayet, Iqbal Malik, Ghada Mikhail, Bon-Kwon Koo, Darrel Francis, Simon Redwood, Carlo Di Mario, Justin 
Davies, Imperial College London, London, United Kingdom
introduction: Adoption of fractional flow reserve (FFR) remains low (6-8%), partly because of the time, cost and potential inconvenience 
associated with vasodilator administration. The instantaneous wave-Free Ratio (iFR) is a pressure-only index of stenosis severity calculated without 
vasodilator drugs. Before outcome trials test iFR as a sole guide to revascularisation, we evaluate the merits of a hybrid iFR-FFR decision-making 
strategy for universal adoption of coronary physiological assessment.
methods: Coronary pressure traces from 577 stenoses were analysed. iFR was calculated as the ratio between Pd and Pa in the resting diastolic 
wave-free window. A hybrid iFR-FFR strategy was evaluated, by allowing iFR to defer some stenoses (where negative predictive value is high) and treat 
others (where positive predictive value is high), with adenosine being given only to patients with iFR in between those values.
results: For a fixed FFR cut-off of 0.8, an iFR of <0.86 could be used to confirm treatment (PPV of 92%), whilst an iFR value of >0.93 could be 
used to defer revascularisation (NPV of 91%). Limiting vasodilator drugs to cases with iFR values between 0.86 to 0.93 would obviate the need for 
vasodilator drugs in 57% of patients, whilst maintaining 95% agreement with an FFR-only strategy. If the 0.75 - 0.8 FFR grey zone is accounted for, 
vasodilator drugs requirement would decrease by 76%.
conclusion: A hybrid iFR-FFR decision-making strategy to guide coronary revascularisation could increase adoption of physiology-guided PCI, by 
more than halving the need for vasodilator administration in clinical practice, whilst maintaining high classification agreement with an FFR-only 
strategy.
